|Indications:||Non-Small Cell Lung Cancer
|Drug Candidate:||Sitravatinib (MGCD516)
|Driver Mutations:||Trk, RET, DDR|
A Phase 1 study evaluating the effects of Sitravatinib (MGCD516) as a treatment for patient with non-small cell lung cancer and other tumor types whose tumors carry genetic alterations of Trk, RET and DDR. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.